Welcome to our dedicated page for CEL-SCI SEC filings (Ticker: CVM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Multikine trial read-outs, LEAPS patents and cash-runway projections make CEL-SCI’s disclosures some of the most technical in biotech. Finding Phase 3 timelines, FDA correspondence or insider purchases inside a 300-page 10-K can stall decision-making.
Stock Titan solves that problem. Our AI-powered engine turns every CEL-SCI annual report into a CEL-SCI annual report 10-K simplified summary, flags liquidity updates in each CEL-SCI quarterly earnings report 10-Q filing, and decodes CEL-SCI 8-K material events explained — like trial milestones or financing rounds — in plain English. Need real-time alerts? The platform streams CEL-SCI Form 4 insider transactions real-time so you can monitor CEL-SCI executive stock transactions Form 4 before market-moving announcements.
Every filing type is covered and searchable:
- 10-K & 10-Q: cash burn analysis, R&D spend, Multikine progress
- 8-K: rapid updates on trial data, regulatory news, or financing
- Form 4: CEL-SCI insider trading Form 4 transactions with AI context
- DEF 14A proxy: CEL-SCI proxy statement executive compensation tied to clinical milestones
Whether you’re comparing quarter-over-quarter R&D expenses, assessing dilution risk, or simply seeking CEL-SCI SEC filings explained simply, our platform delivers. Save hours with concise AI highlights, track filings the moment they hit EDGAR, and turn “understanding CEL-SCI SEC documents with AI” from a goal into your daily workflow.
Hamilton Beach Brands Holding Company (HBB) Form 4 filing shows Director Paul D. Furlow acquired 1,610 Class A common shares on 07/01/2025. The transaction is coded “A” and reflects “Required Shares” granted under the Non-Employee Directors’ Equity Compensation Plan. After the award, Furlow’s direct beneficial ownership stands at 67,125 shares. No shares were sold, and no derivative securities were reported. The filing represents routine board compensation and does not materially affect the company’s capital structure.
Inozyme Pharma, Inc. (NASDAQ: INZY) filed Post-Effective Amendment No. 1 to deregister securities remaining under two previously effective shelf Registration Statements on Form S-3 (Nos. 333-258702 and 333-275364). The shelves collectively covered up to $500 million of common stock, preferred stock, debt, depositary shares, subscription rights, warrants and units. As of July 1, 2025, none of the registered securities remain available for sale.
The amendment follows the consummation of Inozyme’s merger with BioMarin Pharmaceutical Inc. Under the Agreement and Plan of Merger dated May 16, 2025, Incline Merger Sub, Inc. merged with and into Inozyme, making Inozyme a wholly-owned subsidiary of BioMarin as of July 1, 2025. Consequently, all outstanding offerings under the shelves were terminated and the company is removing any unsold securities from registration pursuant to its undertaking under Rule 415.
This filing is largely administrative, signaling the formal close-out of Inozyme’s capital-raising capability as a standalone public entity and completing one of the final SEC steps associated with the transaction.
Haleon plc (LSE/NYSE: HLN) filed a Form 6-K to disclose its share capital position as of 30 June 2025. The Company has issued 8,988,533,553 ordinary shares of £0.01 each, of which 3,880,205 are held in treasury. Consequently, the number of ordinary shares carrying voting rights is 8,984,653,348. This denominator should be used by investors to determine whether their holdings trigger disclosure obligations under the FCA’s Disclosure Guidance and Transparency Rules. No other financial data, corporate actions or strategic updates were included in the filing.
Cel-Sci Corp. (CVM) Form 4 filing discloses that Chief Executive Officer and Director Geert R. Kersten purchased 2,292 shares of common stock on 06/30/2025 at a price of $2.29 per share. Following the transaction, Kersten directly holds 43,638 shares. No derivative security activity was reported. The filing was signed on 07/01/2025 and represents a single-person submission under Section 16 reporting requirements.
FAQ
What is the current stock price of CEL-SCI (CVM)?
What is the market cap of CEL-SCI (CVM)?
What is the core focus of CEL-SCI Corp?
How does CEL-SCI Corp develop its therapies?
What is Multikine and how is it significant?
What role does the LEAPS platform play in the company’s pipeline?
How does CEL-SCI Corp position itself within the competitive biotechnology sector?
What therapeutic areas does CEL-SCI Corp target?
How does CEL-SCI Corp ensure the credibility of its research?
What distinguishes CEL-SCI Corp's approach to immunotherapy?
